Magazine

Table: What's in Store for J&J?


Possible targets for the health-care giant:

SCIOS

Its new drug for heart failure could bring in $500 million a year.

GILEAD SCIENCES

Its new HIV drug is off to a good start. Some analysts believe it could generate close to $1 billion in sales.

CEPHALON

Provigil, its fast-growing drug for narcolepsy, may eventually be used for a range of other sleep disorders--and garner $700 million in sales.

CV THERAPEUTICS

A drug in the works for angina could be worth $500 million a year.


Best LBO Ever
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus